| Business Summary | | Radiance
Medical
Systems,
Inc.
is
developing
proprietary
devices
to
deliver
radiation
to
prevent
the
recurrence
of
blockages
in
arteries
following
balloon
angioplasty,
vascular
stenting
and
other
interventional
treatments
of
blockages
in
coronary
and
peripheral
arteries.
The
Company
incorporates
its
proprietary
RDX
technology
into
catheter-based
systems
that
deliver
beta
radiation
to
the
site
of
a
treated
blockage
in
an
artery
in
order
to
decrease
the
likelihood
of
restenosis.
The
application
of
beta
radiation
inside
the
artery
at
the
site
of
a
blockage
has
proven
clinically
effective
in
inhibiting
cell
proliferation,
a
cause
of
restenosis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Radiance
Medical
Systems,
Inc.
designs,
develops,
manufactures
and
markets
catheters
used
to
treat
certain
vascular
diseases,
which
enable
physicians
to
deliver
therapeutic
radial
force,
stents,
drugs
or
contrast
media
to
the
treatment
site.
For
the
six
months
ended
6/01,
sales
fell
21%
to
$3.9
million.
Net
loss
totalled
$6.4
million,
up
from
$2.6
million.
Revenues
reflect
increasing
competition.
Higher
loss
reflects
higher
expenditures
for
US
clinical
trials. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Michael Henson, 55 Chairman | $437K | $17K | Jeffrey Thiel, 45 Pres,
CEO, Director | 237K | -- | Stephen Kroll, 54 CFO,
VP of Fin. and Admin., Sec. | 230K | -- | Paul Molloy, 39 Sr.
VP of Sales and Marketing | -- | -- | Joseph Bishop, 36 VP-Operations | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|